Compare Futu Holdings Ltd (FUTU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Novartis AG — how do they compare? Futu Holdings Ltd trades at $105.39 (market cap $15.24B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 19.6× Futu Holdings Ltd's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| FUTU | NVS | |
|---|---|---|
Market Cap | $15.24B | $298.18B |
Sector | Financials | Health |
52-Week High | $199.04 | $168.62 |
52-Week Low | $89.76 | $119.31 |
Enterprise Value | $15.09B | $339.50B |
Dividend Yield | 2.39% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings Limited (FUTU) trades at $109.02, up 4.31% today, with a bullish technical signal from moving averages and strong support at $106. The company reported robust 2025 revenue of $22.85 billion and net income of $11.34 billion, with a high net margin of 49.62%. Valuation ratios appear reasonable, with a P/E of 12.07 and P/S of 5.05. However, recent earnings misses in Q1 2026 and a securities class action lawsuit deadline on August 25, 2026, introduce near-term uncertainty.
The outlook for FUTU is mixed: strong profitability and analyst buy ratings (58% consensus) support upside, but legal risks and earnings volatility pose challenges. Investors should weigh solid fundamentals against regulatory and litigation headwinds, with technical levels suggesting $111 as immediate resistance.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
